Urine drug testing, in-office imaging, and behavioral health integration are legitimate revenue streams for pain management practices – and three of the most enforcement-heavy areas in healthcare compliance. The distinction between a defensible program and a liability is almost entirely operational.
Key Takeaways
- Urine drug testing in pain management is clinically appropriate and reimbursable when ordered for medical necessity, documented correctly, and billed at the appropriate code level. It is also one of the most heavily scrutinized billing areas in HHS-OIG enforcement.
- The Stark Law in-office ancillary services exception allows qualifying group practices to refer patients for designated health services, including imaging and lab, within the practice – but the exception has specific requirements that must be met and maintained.
- Presumptive drug testing (immunoassay) and definitive drug testing (chromatography/mass spectrometry) are billed differently and have different medical necessity standards. Billing definitive testing on every patient regardless of clinical indication is a pattern that has produced large-dollar enforcement settlements.
- Behavioral health integration – whether through co-located psychologists or collaborative care models – can improve outcomes and generate legitimate revenue, but compliance with anti-kickback rules on referral arrangements requires careful structure.
Pain management practices are well-positioned to offer ancillary services that both serve patients and generate revenue outside the professional fee. Urine drug testing, diagnostic imaging, and behavioral health integration each have genuine clinical roles in comprehensive pain management. They also represent three of the most scrutinized areas in federal healthcare enforcement. A practice that adds any of them without building the compliance infrastructure first is not expanding its revenue; it is expanding its exposure.
This is not a reason to avoid these service lines. The DOJ, OIG, and CMS have pursued enforcement actions not against practices that offered urine drug testing, imaging, or behavioral health services, but against practices that ordered services without medical necessity, billed at levels the documentation did not support, or structured referral arrangements that violated the Anti-Kickback Statute or Stark Law. The distinction between a defensible ancillary program and the kind that generates a settlement demand is almost entirely in the operational design and the documentation discipline.
Urine Drug Testing: The Most Important Distinction to Get Right
Urine drug testing in a pain management practice serves a legitimate clinical purpose: monitoring patient adherence to prescribed medications and identifying the use of substances that were not prescribed. CMS and commercial payers reimburse for this testing when it is ordered for medical necessity, performed at the appropriate level of complexity, and billed at the correct code. The compliance problem in this service line almost always comes from one of three places: ordering tests that are not medically necessary for the individual patient, billing definitive testing when presumptive testing was ordered and is all that is clinically indicated, or billing validity testing separately when it is not separately reimbursable.
The coding framework matters. Presumptive testing – typically immunoassay strips or point-of-care devices that confirm or deny the presence of a drug class – is coded under G0477 through G0481, depending on the number of drug classes tested. Definitive testing – chromatography or mass spectrometry that identifies specific drugs and metabolites – is coded under G0483 and is priced considerably higher. The medical necessity distinction between them is real: a patient with an unexpected positive on a presumptive screen may legitimately warrant definitive confirmation. A policy of ordering definitive testing on every patient at every visit, regardless of clinical indication, is the pattern that has produced the large-dollar enforcement settlements in this area. It is not a billing strategy. It is a liability.
If your practice performs urine drug testing in-office, maintain a written policy governing when each testing level is ordered, what documentation in the chart supports each level, and how often testing is performed for each patient category. That policy should be tied to clinical decision-making, not to revenue optimization. Payers have become sophisticated at identifying statistical outliers – practices that bill definitive testing at rates far above peers, that test every patient at every visit – and those patterns generate audits. The defense against an audit is documentation showing that every test ordered had a specific clinical reason.
The question to ask before ordering any drug test is not “will this be paid?” It is “what clinical decision will this result change, and have I documented why I need it for this patient today?” If the answer is “none” and “I haven’t,” the test should not be ordered.
In-Office Imaging
Diagnostic imaging within a pain management practice – fluoroscopy for procedure guidance, plain films, and in some practices MRI or ultrasound – can fall under both Stark Law analysis and the in-office ancillary services exception (IOAS). Diagnostic imaging is a designated health service under Stark, meaning a physician’s referral of Medicare patients to an entity in which the physician has a financial interest is prohibited unless an exception applies. The IOAS exception, when its requirements are met, permits qualifying physician group practices to offer these services within the practice. The requirements are specific: the service must be furnished personally by the referring physician, by another physician in the same group practice, or by a supervised individual under the supervision of the referring physician or another group physician; the service must be furnished in the same building as the physician’s office or in a centralized building used by the group; and the billing must comply with the applicable reassignment rules.
Fluoroscopy used to guide a procedure the physician is performing is straightforwardly within the IOAS exception – it is furnished by the physician in the course of the procedure. The more complex analysis arises when a pain practice refers patients for separate imaging studies and has a financial interest in the imaging entity. That structure requires careful legal review before implementation. The short version: get a healthcare attorney familiar with Stark to review the specific arrangement before you sign any lease, equipment agreement, or revenue-sharing arrangement with an imaging facility. The IOAS exception is viable for many pain practices, but it is not self-executing and its requirements are not flexible.
Behavioral Health Integration
The clinical evidence for behavioral health integration in chronic pain management is well-established. Pain catastrophizing, depression, and anxiety are co-morbid in a high proportion of chronic pain patients and affect both treatment adherence and outcomes. Practices that integrate psychologists, licensed clinical social workers, or collaborative care models are addressing a real clinical need and, when structured correctly, can generate revenue from evaluation and treatment services that were previously un-captured.
The compliance structure depends on how the behavioral health provider is engaged. A salaried or W-2 employee behavioral health clinician working within the practice, billing under the practice’s NPI, is the most straightforward arrangement. Fee-for-service arrangements that involve cross-referral between a pain practice and an independent behavioral health provider need to be reviewed against the Anti-Kickback Statute, because any arrangement where referrals flow between parties with a financial relationship can raise AKS risk if not structured with a commercially reasonable, fair-market-value compensation arrangement that does not take into account the volume or value of referrals. This is not an area where informal arrangements survive scrutiny. It is an area where a written, documented, fair-market-value compensation arrangement is the minimum requirement.
The Medical Necessity Principle Applies to All Three
Across urine drug testing, imaging, and behavioral health, the common compliance principle is medical necessity: the service is ordered because a specific patient needs it for their specific clinical situation, the clinical reasoning is documented in the chart, and the billing code reflects what was actually performed and documented. Ancillary services that exist primarily to generate revenue, ordered by protocol rather than by clinical indication for each patient, are what enforcement actions are built from. Services ordered on a defensible clinical basis, documented thoroughly, and billed correctly survive scrutiny regardless of volume.
From the Field
A five-physician pain management group in the Southwest had been operating an in-office urine drug testing program for three years. A compliance review prompted by a payer audit letter revealed that the practice’s testing policy had never been written down, that definitive testing was being ordered at a rate that significantly exceeded regional peers, and that chart documentation supporting the test level was inconsistent across physicians. No enforcement action resulted from the initial audit, but the practice recognized its exposure. Our fractional COO engagement drafted the written testing policy collaboratively with the physicians, created a chart documentation template that linked testing level to specific clinical criteria, ran a training session for all clinical staff on the policy and the documentation requirement, and established a quarterly internal audit of a sample of drug testing claims. Testing volume decreased modestly as the policy filtered out non-indicated orders, but per-test documentation quality improved substantially. On a follow-up payer audit eighteen months later, every audited claim was supported. The practice closed the compliance gap before it became a settlement conversation.
The Execution Question
Designing a compliant ancillary service program requires two kinds of expertise: legal review of the specific structure against Stark, AKS, and applicable state law, which is the domain of healthcare counsel; and operational implementation of the policies, documentation workflows, and billing practices, which is a management function. A consultant can produce the operational design – the written policy, the documentation template, the audit schedule, the billing protocol. If your practice has a clinical director or compliance coordinator with the capacity and training to implement that design and maintain it, consulting is often the right scope.
Where we see programs erode is in the handoff: a well-designed policy that was never operationalized into staff training and workflow, or that was implemented in month one and not audited since. A fractional executive stays through implementation – running the staff training, testing the documentation workflow against real charts, establishing the audit cadence, and doing the first audit before stepping back. The difference between a compliant program and a liability is usually not the policy document. It is whether the policy was ever actually deployed at the point of care.
Sources
- Anesthesia Business Consultants, The Stark Law In-Office Ancillary Services Exception for Pain Management Practices — https://www.anesthesiallc.com/publications/anesthesia-industry-ealerts/64-communique/past-issues/winter-2010/136-the-stark-laws-in-office-ancillary-services-exception-in-office-ancillary-arrangements-remain-viable-for-pain-management-practices
- U.S. Department of Justice, Pain Management Clinics Settle Medicare Civil Fraud Claims — https://www.justice.gov/usao-edva/pr/pain-management-clinics-settle-medicare-civil-fraud-claims
- HHS Office of Inspector General, Combating the Opioid Epidemic — https://oig.hhs.gov/reports/featured/combating-the-opioid-epidemic/
- KFF, Medicare Advantage Insurers Made Nearly 53 Million Prior Authorization Determinations in 2024 — https://www.kff.org/medicare/medicare-advantage-insurers-made-nearly-53-million-prior-authorization-determinations-in-2024/
More in the Pain Management Series
- Where You Perform the Procedure Is Almost As Important As What You Bill — the site-of-service decision that drives more revenue per procedure than almost any other choice an interventional practice makes.
- Prior Authorization Is Not Going Away. Build the System That Handles It. — the prior authorization process that determines whether your scheduled procedures get paid.
- A Defensible Prescribing Program Is Not Optional. Build It Before You Need It. — the controlled substance compliance program that protects the practice and the license when regulators look.
- A Full Schedule Is Not a Productive Schedule. Design the Difference. — the staffing and scheduling design that separates a productive procedure-based practice from a busy one.